iCAD has revealed that its ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) has been granted clearance by the U.S. Food and Drug Administration (FDA).
This next-generation AI solution, using advanced deep learning convolutional neural networks (CNN), offers improved cancer detection and accuracy, with a 6.3% enhancement in performance over the previous version.
This advancement helps to identify hard-to-detect, aggressive cancers while reducing false positives. A new feature also allows clinicians to incorporate previous exams into the analysis of current screenings.
ProFound Detection Version 4.0 builds on this legacy with enhanced detection and precision. Following FDA clearance.
The new version presents significant growth opportunities for iCAD, as both existing and new customers upgrade to the latest version and adopt cloud-based deployment and subscription services.
This shift to the cloud is expected to drive steady growth in iCAD's Annual Recurring Revenue (ARR) and enable healthcare facilities to remain at the forefront of AI technology, benefiting from scalability, continuous updates, and greater operational efficiency.
Compared to its predecessor, ProFound Detection Version 4.0 offers a 22% improvement in detecting difficult and aggressive cancer types, including 50% improvement in identifying cancers in dense breast tissue, 60% improvement in detecting invasive lobular cancers, 21% improvement in detecting invasive cancers, and 38% improvement in identifying cancers smaller than 1 cm.
ProFound Detection Version 4.0 also provides more accurate lesion marking, with an 18% improvement in cases with no marks, which reduces false positives. Key improvements include 20% fewer marks related to vascular calcifications and 51% fewer marks related to non-vascular calcifications.
The integration of prior exam data into current case assessments offers clinicians improved accuracy and insight, mirroring the approach radiologists use when reviewing current and past screenings. This feature enhances clinical decision-making, streamlining workflows and improving the overall interpretation experience.
Source: https://www.icadmed.com/about/news-events/press-releases/icads-profound-detection-version-4-0-gains-fda-clearance/
